INCA036873 not checked

Incyte Corporation

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total · 1 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Solid Tumors, Hematologic Malignancies
Main trialPhase 1
“A study to evaluate the safety and tolerability of INCA036873 in participants with advanced solid tumors and hematological malignancies.”In the company’s words, NCT07195916 on ClinicalTrials.gov

Other drugs for Solid Tumors

All 2440 drugs for Solid Tumors

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 18 Aug 2028 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow INCA036873

Following is part of Solo: you see every change to INCA036873 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in